Lupin Spins Out Two Oncology Assets into Kaveri Therapeutics, Retains 82.2% Controlling Stake
Key Insights
Lupin Limited has spun out its two clinical-stage oncology programs, LNP7457 (PRMT5 inhibitor) and LNP8701 (SOS1 (search) inhibitor), into U.S.-based Kaveri Therapeutics Inc. (search)
In exchange for exclusive perpetual global licensing rights, Lupin Inc. acquired an 82.2% equity stake in Kaveri, with the transaction valued at $1.6 million.
Both assets have demonstrated encouraging early clinical data at ASCO meetings, with Phase 1b trials planned for each program.
Lupin Limited, the Mumbai-headquartered pharmaceutical company, has announced the spin-out of two oncology programs into Kaveri Therapeutics Inc. (search), a newly incorporated U.S.-based clinical-stage oncology company. Under the agreement, Lupin Inc., a wholly owned subsidiary, grants Kaveri exclusive perpetual global licensing rights to LNP7457, a PRMT5 inhibitor, and LNP8701, a SOS1 (search) inhibitor, in exchange for a commanding 82.2% equity stake comprising 332,000 Common Shares. The transaction and licensed assets are valued at $1.6 million.
Kaveri Therapeutics, incorporated on May 20, 2026, will operate independently under the leadership of CEO Kristi Jones and Chief Medical Officer Dr. Robert Pierce, both described as seasoned biopharmaceutical executives. The company will assume complete operational and fundraising responsibility for advancing global clinical trials, with plans to seek external capital to fund these efforts.
Clinical Progress and ASCO Data
Both oncology programs have already generated encouraging clinical data presented at the American Society of Clinical Oncology meetings. LNP7457, targeting PRMT5, was featured at ASCO 2025, where a Phase 1a dose-escalation study in advanced or metastatic solid tumors (search) demonstrated that the drug was safe and well tolerated, with a desirable PK/PD profile. The maximum tolerated dose and recommended Phase 2 dose were established, supporting advancement into Phase 1b trials.
LNP8701, a SOS1 (search) inhibitor, was presented at ASCO 2026. The Phase 1a first-in-human study in metastatic solid tumors showed favorable safety and pharmacokinetics. Preliminary efficacy signals included patients achieving stable disease, with some completing over 12 treatment cycles. Early anti-tumor activity signals were observed, and Phase 1b trials are planned.
Strategic Rationale
Vinita Gupta, CEO of Lupin, stated that the company is proud to have pioneered these oncology assets and looks forward to their advancement through Kaveri. She emphasized that the strength of the programs, combined with Kaveri's seasoned leadership team, positions them to accelerate the development of targeted oncology therapies.
The transaction reflects an evolving model among leading Indian pharmaceutical players, where specialized novel assets are separated from core generic business operations. By spinning these assets into a dedicated independent U.S. vehicle, Lupin shifts future clinical development costs and fundraising efforts to Kaveri while retaining an 82.2% dominant equity stake that preserves significant upside should clinical trials prove successful.
Kaveri Therapeutics is focused on biomarker-driven clinical development and rational combination strategies to advance small-molecule therapies for hard-to-treat cancers. Lupin, a diversified pharmaceutical leader, distributes products in over 100 countries spanning branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.